Rights Issue Completes Substantially Oversubscribed

NZX/ASX Announcement
25 June 2026
Rights Issue Completes Substantially Oversubscribed

TruScreen Group Limited (NZX/ASX:TRU) (TruScreen or TRU or Company) is pleased to
advise that further to the announcement of 21 May 2026 “TruScreen announces the opening
of a NZ$2.9m capital raise”, the Company has now finalised the Renounceable Rights Issue
and shortfall bookbuild which was substantially oversubscribed.
The Company received applications for 171,653,080 shares being 15% over the rights issue
offer of 149,464,986 shares. The Directors have determined to retain the Offer price as the
Bookbuild price for the shortfall applications and the additional shares applied for over and
above the offer.
The Rights issue applications will be dealt with as follows:
1. Rights issue entitlements will be allotted on the 30 June 2026, in the amount of
80,616,522 shares at the Offer price of NZ$0.013/A$0.011.
2. The Shortfall shares will be allotted on 30 June 2026, in the amount of 68,848,464 shares
at the bookbuild price of NZ$0.013/A$0.011. The allocation has been scaled based on a
shareholders holding on the record date, being 28 May 2026.
3. The directors intend to seek shareholder approval to allocate shares applied for
exceeding the Rights Offer, in the amount of 22,188,094 at the bookbuild price of
NZ$0.013/A$0.011. The General Meeting is expected to be held on or around 28 July
2026.
Tony Ho Chairman commented, “we are delighted with the strong support that we have
received for this Rights Issue from our shareholders. This brings the total amount of the
Placement and Rights Issue capital raise to just over NZ$4 million. These funds will allow the
Company to capitalise on the significant opportunities we have in the year ahead.”
This announcement has been approved by the Board.

Ends

For more information, visit www.truscreen.com or contact:
Tony Ho
Non-Executive Chairman
tonyho@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com
Omar Taheri
Media & Investor
Relations
omar
@sparkplus.org

About TruScreen:

TruScreen Group Limited (NZX/ ASX: TRU) is a medical device company that has developed and manufactures

an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low
level of optical and electrical stimuli.
TruScreen’s cervical screening technology enables cervical screening, negating sampling and processing of
biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel
and supporting laboratory infrastructure.
The TruScreen device, TruScreen Ultra
®
, is registered as a primary screening device for cervical cancer screening.
The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA
(Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico).
It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has
distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices
marketed and sold in China.
TruScreen technology is recognised in CSCCP’s (Chinese Society for Colposcopy and Cervical Pathology) China
Cervical Cancer Screening Management Guidelines and the COGA Blue Book.
In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical
List, for use in Vietnam’s public and private healthcare sectors and in 2024 was added to the Russian guidelines
for the screening of cervical cancer.
In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To date,
over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi
Arabia. TruScreen’s vision is “A world without the cervical cancer”.
To learn more, please visit: www.truscreen.com/.
*Based on Single Use Sensor sales.

About DaltonBio:

DALTON BioSciences ("DALTONbio") is a global, innovative medical technology company focusing on in vitro
diagnosis (IVD) in women's health and oncology. DALTONbio is the leader in human papillomavirus (HPV)
nucleic acid testing and comprehensive cervical cancer detection and screening. Its HPV DNA detection kits
(DH HPV test series) are the world's only products based on its third-generation proprietary hybrid-capture
technology, which provides HPV genotyping without requiring nucleic acid extractions and amplifications. This
technology is well-suited for the detection of high-risk types of HPV and cervical cancer screening.
DALTONbio’s exceptional, clinically proven products have served tens of millions of lives in the world. They
have aided health professionals in detecting, diagnosing, and treating illnesses earlier and more effectively,
resulting in healthier people everywhere, every day.
To learn more, please visit: www.daltonbio.com/.